INM

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.13
Percentage change -3.85	%

Peers: AVDL CRBP TVRD EYPT ALT ASRT OCGN ABEO AYTU CTXR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.63	Insider Own	0.39%	Shs Outstand	1.21M	Perf Week	32.65%
Market Cap	3.92M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.20M	Perf Month	32.65%
Enterprise Value	0.05M	PEG	-	EPS next Q	-	Inst Own	7.19%	Short Float	2.74%	Perf Quarter	57.77%
Income	-8.31M	P/S	0.80	EPS this Y	-	Inst Trans	-41.32%	Short Ratio	0.01	Perf Half Y	-30.26%
Sales	4.92M	P/B	0.56	EPS next Y	-	ROA	-73.43%	Short Interest	0.03M	Perf YTD	-31.43%
Book/sh	5.82	P/C	0.83	EPS next 5Y	-	ROE	-91.71%	52W High	15.70 -79.29%	Perf Year	-38.21%
Cash/sh	3.91	P/FCF	-	EPS past 3/5Y	70.17% 53.87%	ROIC	-111.70%	52W Low	1.72 88.95%	Perf 3Y	-98.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	15.75%	Volatility	21.50% 20.18%	Perf 5Y	-99.90%
Dividend TTM	-	EV/Sales	0.01	EPS Y/Y TTM	48.59%	Oper. Margin	-169.65%	ATR (14)	0.55	Perf 10Y	-99.86%
Dividend Ex-Date	-	Quick Ratio	3.04	Sales Y/Y TTM	-12.53%	Profit Margin	-168.90%	RSI (14)	55.31	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.49	EPS Q/Q	46.01%	SMA20	10.04%	Beta	0.38	Target Price	400.00
Payout	-	Debt/Eq	0.12	Sales Q/Q	7.59%	SMA50	13.21%	Rel Volume	0.06	Prev Close	3.38
Employees	13	LT Debt/Eq	0.06	Earnings	May 13 BMO	SMA200	-13.60%	Avg Volume	3.12M	Price	3.25
IPO	Nov 17, 2008	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	201,735	Change	-3.85%

Jun-27-25 07:00AM	InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules (Newsfile)
Jun-25-25 08:00AM	InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules (Newsfile)
Jun-24-25 07:00AM	InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study (Newsfile) +57.96%
Jun-13-25 04:30PM	InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA (Newsfile) -5.95% -6.32%
May-12-25 06:00PM	InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile) +14.91%
06:54PM	Loading…
Feb-12-25 06:54PM	InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile)
Feb-03-25 07:30AM	InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration (Newsfile)
Jan-22-25 07:30AM	InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds (Newsfile) -20.79%
Jan-21-25 07:30AM	InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study (Newsfile)
Dec-18-24 08:00PM	InMed Announces Results of 2024 Annual General Meeting (Newsfile) -16.18%
Dec-17-24 04:56PM	InMed Enters Into Standby Equity Purchase Agreement (Newsfile)
Nov-19-24 07:30AM	InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System (Newsfile)
Nov-14-24 04:45PM	InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile) +9.29% -15.73%
Nov-08-24 04:44PM	InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules (Newsfile)
Nov-05-24 08:30AM	InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules (Newsfile) -7.41%
07:30AM	Loading…
Oct-28-24 07:30AM	InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease (Newsfile) +6.63%
Oct-24-24 08:00AM	InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease (Newsfile)
Oct-22-24 08:00AM	InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board (Newsfile) +10.00%
Sep-30-24 08:00AM	InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Sep-20-24 04:30PM	InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date (Newsfile) -12.16%
Aug-21-24 07:30AM	InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents (Newsfile)
Aug-20-24 07:30AM	InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease (Newsfile) +191.35%
Jul-30-24 08:00AM	InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data (Newsfile) -17.59%
Jun-28-24 06:00AM	7 F-Rated Growth Stocks to Avoid Right Now: June 2024 (InvestorPlace)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-10-24 05:18PM	InMed to Present at the Emerging Growth Conference (Newsfile)
Jun-06-24 07:38AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -15.51%
May-14-24 10:53PM	INM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024 (InvestorPlace)
08:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
08:00AM	Loading…
Apr-18-24 08:00AM	InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board (Newsfile)
Apr-16-24 08:00AM	InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration (Newsfile)
Apr-04-24 08:00AM	InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies (Newsfile)
Mar-20-24 08:30AM	InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance (Newsfile)
Feb-13-24 05:41PM	InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update (Newsfile)
Feb-09-24 08:00AM	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer (Newsfile)
Jan-18-24 04:41PM	InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET (Newsfile)
Jan-16-24 08:00AM	InMed Pharmaceuticals Provides Business Update and Milestones for 2024 (Newsfile)
Dec-19-23 06:03PM	InMed Announces Results of 2023 Annual General Meeting (Newsfile) +5.54%
Nov-29-23 08:00AM	InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration (Newsfile) +21.74%
Nov-14-23 08:04AM	InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Nov-02-23 08:00AM	InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 (Newsfile)
Oct-26-23 07:15PM	InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules (Newsfile) -9.53% -15.93%
Oct-25-23 09:00AM	Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today? (InvestorPlace) -24.18%
Oct-24-23 04:38PM	InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules (Newsfile) +70.53%
07:30AM	InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies (Newsfile)
Sep-29-23 01:21PM	InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Sep-22-23 06:15PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (Newsfile)
Sep-07-23 08:30AM	InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference (Newsfile)
Jul-21-23 07:30AM	InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET (Newsfile) +6.05%
Jul-20-23 07:30AM	InMed Provides Update on BayMedica Rare Cannabinoid Business (Newsfile) +5.32%
Jun-22-23 02:28PM	Why Are InMed Pharmaceuticals Stock Trading Lower Today (Benzinga) -13.57%
07:30AM	InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa (Newsfile)
Jun-01-23 07:30AM	InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting (Newsfile)
May-24-23 06:51PM	InMed to Participate in Upcoming Virtual Investor Events (Newsfile)
May-18-23 05:00PM	InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET (Newsfile) +20.87%
May-15-23 12:33PM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Mar-28-23 07:30AM	InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa (Newsfile) -9.45%
Mar-13-23 07:30AM	InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions (Newsfile) +7.62%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on March 8 Register Now (GlobeNewswire)
Mar-06-23 06:00PM	InMed to Participate in Upcoming Investor Events (Newsfile) +9.82%
Feb-17-23 05:00PM	InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.50%
Feb-09-23 09:41PM	InMed Submits Form 12b-25 (GlobeNewswire)
Jan-10-23 07:30AM	InMed Provides Business Update and Milestones for 2023 (GlobeNewswire) +36.09%
Dec-15-22 06:17PM	InMed Announces Results of 2022 Annual General Meeting (GlobeNewswire) -7.00%
Dec-12-22 06:47PM	InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor (GlobeNewswire)
Nov-23-22 12:18PM	Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update (Zacks)
Nov-21-22 05:00PM	InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market (GlobeNewswire) -6.16% +5.02%
Nov-18-22 08:00AM	InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market (GlobeNewswire) -28.12%
Nov-17-22 10:32AM	InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program (Zacks)
07:30AM	InMed Provides Update on Management Changes (GlobeNewswire)
Nov-16-22 12:13PM	InMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson's (MarketWatch) +36.33%
07:00AM	InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding (GlobeNewswire)
Nov-11-22 06:51PM	InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.33%
Nov-10-22 07:30AM	Registration Now Open For Tribe Publics Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMeds Management Team On November 17, 2022 (GlobeNewswire) +8.30%
Oct-26-22 07:30AM	InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week (GlobeNewswire) +9.12%
Oct-24-22 10:13AM	10 Best Pharma Stocks To Buy Now (Insider Monkey) -17.41%
Sep-23-22 12:29PM	InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update (GlobeNewswire) -19.51%
Sep-19-22 06:00PM	InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022 (GlobeNewswire) -8.13%
Sep-13-22 05:12PM	InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market (GlobeNewswire) -35.73% -8.86%
Sep-09-22 05:00PM	InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market (GlobeNewswire) +24.24% +70.42%
Sep-08-22 02:08PM	InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business (GlobeNewswire)
Aug-23-22 05:00PM	InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria (GlobeNewswire) -21.02%
Aug-09-22 07:30AM	InMed Announces Changes to its Board of Directors (GlobeNewswire)
Jul-25-22 07:30AM	InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa (GlobeNewswire)
Jul-18-22 07:30AM	InMed Announces Appointment of Chief Operating Officer (GlobeNewswire)
Jul-12-22 11:33PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (GlobeNewswire) -5.18%
Jun-14-22 07:30AM	InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions (GlobeNewswire)
Jun-09-22 07:30AM	InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector (GlobeNewswire)
Jun-06-22 06:49PM	InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jun-02-22 08:00AM	InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -6.04%
May-13-22 08:45AM	InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-05-22 07:30AM	InMed to Supply Rare Cannabinoids to Radicle Sciences Radicle Energy Study to Assess the Health Effects of THCV (GlobeNewswire) -8.36%
May-03-22 12:00PM	InMed Pharmaceuticals (INM): Notable Launches of High-Value Rare Cannabinoids (ACCESSWIRE)
Apr-28-22 07:30AM	InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert (GlobeNewswire) +8.15%
Apr-21-22 07:30AM	InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector (GlobeNewswire)
Apr-19-22 07:30AM	InMed to Participate in Upcoming Investor Conferences in April and May 2022 (GlobeNewswire)

InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It operates through the InMed Pharma and BayMedica segments. The InMed Pharma segment is organized around the research and development of small molecule pharmaceuticals drug candidates. The BayMedica segment focuses on the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MANCINI ALEXANDRA DIANE JANET	Consultant	Jul 31 '24	Sale	0.18	240	42	0	Aug 02 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

InMed Pharmaceuticals Inc

Upgrade your FINVIZ experience